Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Insulin Glulisine (compound)

Name: insulin glulisine
Name (isomeric): DB01309
Drug Type: biotech
Brand: Apidra
Category: Hypoglycemic Agents, Antidiabetic
CAS number: 207748-29-6
Indication: For the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents.
Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular ...
show more »
Mechanism of Action:
Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylat...
show more »
Absorption: Absolute bioavailability following subcutaneous administration is approximately 70%. Time to maximum plasma concentration is approximately 60 minutes.
Half Life: 42 minutes
Toxicity: Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia.
Affected organisms: Humans and other mammals
Drug interaction:
Somatropin recombinantSomatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars.
FenfluramineFenfluramine increases the effect of insulin
AcebutololThe beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.
EsmololThe beta-blocker, esmolol, may decrease symptoms of hypoglycemia.
ClofibrateIncreases the effect of insulin
show more »